Shares of Usana Health Sciences (NASDAQ: USNA) are down 25% after the company reported lower than expected first quarter sales, and forecast a drop of 20% in full-year earnings.
In the press release announcing the results, Usana blamed "disappointing results from new promotional and incentive activities, economic uncertainties in the U.S., as well as the lingering effects relating to negative misinformation about the company that appeared in the mass media during 2007."
The "negative misinformation" referred to consisted of a series of reports produced by ex-con turned fraud investigator Barry Minkow, who alleged that the company was operating an illegal pyramid scheme. While the SEC ended its investigation of the company without taking any action, the company's lawsuit against Minkow has not gone so well.
A court tossed out 4 of the company's 5 claims against Minkow, with Judge Tena Campbell saying that the company failed to demonstrate that Minkow's claims were false, writing that their arguments of defamation revolved around "hypertechnical statements representing differing interpretation of data."
Minkow told the Salt Lake Tribune that "The message from this case is if you have accurate information and you don't break the law and you can corroborate your findings, you don't have to fear retribution from the company."
So here's my question for Usana: If Minkow's claims were "negative misinformation," why can't you rebut the substance of his report?
In an email, Minkow told me that he believes that "the credit crisis prevented people from dumping overpriced vitamins or failing business opportunities on their credit card and the same will occur with Herbalife (NYSE: HLF)."
Last updated: February 13, 2012: 09:54 AM
Hot Stocks
DailyFinance Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- SanDisk volatility low into analyst day and sales outlook
- Obama budget requests increase in Pell Grants, Inside Higher Education says
- Stoneridge sees 2012 EPS $1.10-$1.30 vs. consensus $1.13
- Stoneridge Q2 results include $1.72/sh in gains
- Stoneridge reports Q4 diluted EPS $1.56 vs. consensus 22c
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

